William Blair analyst Lachlan Hanbury-Brown downgraded Apellis Pharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Baird Downgrades Apellis Pharmaceuticals (APLS) to NeutralMarch 31, 2026 11:51 AM Needham Downgrades Apellis Pharmaceuticals (APLS) to HoldMarch 31, 2026 11:45 AM Apellis Pharmaceuticals (APLS) call put ratio 1.2 calls to 1 put after Biogen (BIIB) acquiresMarch 31, 2026 10:17 AM Wolfe Research on Apellis Pharmaceuticals (APLS): Biogen deal 'makes sense' at 'good time to sell'March 31, 2026 10:11 AM Biogen to acquire Apellis for $5.6 billion in cash dealMarch 31, 2026 6:59 AM Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyMarch 31, 2026 6:59 AM Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVRMarch 31, 2026 6:45 AM